Asset Details
Do you wish to reserve the book?
Simultaneous administration of mRNA COVID-19 bivalent booster and influenza vaccines
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Simultaneous administration of mRNA COVID-19 bivalent booster and influenza vaccines
Do you wish to request the book?
Simultaneous administration of mRNA COVID-19 bivalent booster and influenza vaccines
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Simultaneous administration of mRNA COVID-19 bivalent booster and influenza vaccines
2023
Overview
The U.S. Food and Drug Administration authorized use of mRNA COVID-19 bivalent booster vaccines on August 31, 2022. Currently, CDC’s clinical guidance states that COVID-19 and other vaccines may be administered simultaneously. At time of authorization and recommendations, limited data existed describing simultaneous administration of COVID-19 bivalent booster and other vaccines. We describe simultaneous influenza and mRNA COVID-19 bivalent booster vaccine administration between August 31–December 31, 2022, among persons aged ≥6 months in the Vaccine Safety Datalink (VSD) by COVID-19 bivalent booster vaccine type, influenza vaccine type, age group, sex, and race and ethnicity. Of 2,301,876 persons who received a COVID-19 bivalent booster vaccine, 737,992 (32.1%) received simultaneous influenza vaccine, majority were female (53.1%), aged ≥18 years (91.4%), and non-Hispanic White (55.7%). These findings can inform future VSD studies on simultaneous influenza and COVID-19 bivalent booster vaccine safety and coverage, which may have implications for immunization service delivery.
Publisher
Elsevier Ltd,Elsevier Limited
Subject
/ Adult
/ COVID-19
/ COVID-19 - prevention & control
/ Female
/ females
/ Food and Drug Administration
/ Humans
/ Influenza Vaccines - adverse effects
/ Influenza, Human - prevention & control
/ Male
/ mRNA
/ mRNA covid-19 bivalent booster vaccine
/ nationalities and ethnic groups
/ Safety
/ Vaccines
